GlassScriptPhysician profile
Elizabeth Y Liu
NPI 1780629931
$2,470.22
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,195 · 2020: $1,276.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $346.24 | 2019-2020 | |
| Novo Nordisk INC | $289.04 | 2019-2020 | |
| Pfizer INC. | $256.00 | 2019-2020 | |
| Lilly USA, LLC | $199.83 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $192.84 | 2019 | |
| Abbvie INC. | $174.96 | 2019-2020 | |
| Allergan, INC. | $171.11 | 2019-2020 | |
| Glaxosmithkline, LLC. | $145.25 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $105.62 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.87 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $56.52 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $53.15 | 2020 | |
| Amarin Pharma, INC. | $52.49 | 2019-2020 | |
| Mylan Specialty L.P. | $49.74 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $42.89 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.96 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $39.84 | 2019 | |
| Redhill Biopharma INC. | $39.34 | 2020 | |
| Horizon Therapeutics Plc | $28.93 | 2019 | |
| Hikma Pharmaceuticals USA | $26.69 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.46 | 2019 | |
| Dermira, INC. | $13.64 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.62 | 2019 | |
| Avion Pharmaceuticals | $13.10 | 2020 | |
| Genentech USA, INC. | $12.50 | 2019 | |
| Daiichi Sankyo INC. | $10.59 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.